Hologic case takes toll on Lunar
Bone densitometry firm Lunar said its ongoing legal battle withHologic will result in unexpectedly high legal costs that willeat into profits for the fourth quarter (end-June). Lunar willprobably post profits for the quarter that are lower comparedto the
Bone densitometry firm Lunar said its ongoing legal battle withHologic will result in unexpectedly high legal costs that willeat into profits for the fourth quarter (end-June). Lunar willprobably post profits for the quarter that are lower comparedto the same period a year ago, when Lunar had net income of $1.7million. The Madison, WI, company did not project a specific figurefor fourth-quarter earnings.
Lunar said legal costs associated with its patent battle withHologic have been higher than expected (SCAN 6/7/95). The caseis scheduled to go to trial Aug. 14 and is expected to last twoweeks, according to the company.
On the positive side, Lunar said it expects to show sharplyhigher revenues when it makes its full quarterly earnings announcementAug. 4. Revenues are expected to be $12.7 million, up 37% comparedto the $9.3 million in sales reported in the same period in 1994.Medicare reimbursement for dual-energy x-ray absorptiometry hasbeen driving sales growth for DEXA scanners this year (SCAN 12/28/94).
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
